December 9, 2022
Indies Pharma Jamaica Limited (INDIES), reported revenues for the twelve months ended October 31, 2022 of $937.28 million (2021: $846.83 million), an increase of 11% year over year. For the quarter, revenues decreased 2% to $209.65 million (2021: $213.54 million).
Cost of sales amounted to a total of $282.32 million (2021: $295.90 million), a 5% decrease year over year. As such, gross profit increased 19% to $654.97 million (2021: $550.93 million). For the quarter, gross profit closed at $137.59 million (2021: $150.68 million).
Other operating income for the year end amounted to $3.84 million (2021: $7.49 million), a decrease of 49% year over year. Administrative expenses increased by 13% to $370.76 million (2021: $326.83 million).
Profit from operations increased 24% to $288.04 million (2021: $231.59 million). For the quarter, profit from operations closed at $51.04 million (2021: $74.69 million).
Foreign exchange loss for FY2022 amounted to $2.23 million (2021: gains of $14.76 million), while finance cost decreased to $59.98 million (2021: $67.79 million).
Profit before tax increased 26% to $225.84 million (2021: $178.56 million). For the quarter, profit before tax amounted to $34.26 million (2021: $71.08 million).
Consequently, net profit for the year increased 26% to $225.84 (2021: $178.56 million). There remained no tax charge year over year. For the quarter, net profit was $34.26 million (2021: $71.08 million).
Total comprehensive income totalled $225.84 million (2021: $467.03 million), a 52% decrease year over year. For the quarter, total comprehensive income amounted to $34.26 million (2021: $71.08 million).
Earnings per share (EPS) for the period amounted $0.17 (2021: $0.13). For the quarter, EPS totalled $0.026 (2021: $0.056). The number of shares used in the calculations is 1,332,536,649. The stock last traded on December 8, 2022 at $2.88 with a corresponding P/E ratio of 16.99 times.
Balance Sheet at a glance:
Total assets amounted to $2.16 billion (2021: $2.04 billion), 6% more year over year. This was primarily due to the 201% increase in ‘Right of use asset’ which closed $119.26 million (2021: $39.62 million).
Shareholders’ Equity totalled $1.18 billion (2021: $1.11 billion) resulting in a book value per share of $0.89 (2021: $0. 83).
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.